Several observational studies have reported associations of hyperphosphatemia with increased risks for cardiovascular events and mortality in individuals with chronic kidney disease (CKD).1 The KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline on the management of CKD−mineral and bone disorder recommends keeping serum phosphorus levels within the normal range for patients with CKD stages 3 to 5, including those receiving dialysis who are using dietary measures or certain medications, so-called phosphate binders.